PRECISION BIOSCIENCES

Live / Registered — Registered (as of 25 Apr 2023)

What this means for you

Registered since 25 Apr 2023. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97117501
Registration number
7034223
Mark type
Stylized text
Filed
10 Nov 2021
Published for opposition
20 Dec 2022
Registered
25 Apr 2023
Attorney of record
Eva Gullick Frongello

Goods and services

  • Class 001 — Chemicals: genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno
  • Class 005 — Pharmaceuticals: pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use
  • Class 042 — Scientific and technological services: research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
  • Class 044 — Medical, beauty and agricultural services: Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer

Owner

Prosecution history

  • 08 May 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 08 May 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 08 May 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 08 May 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 08 May 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 25 Apr 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 25 Apr 2023 — REGISTERED-PRINCIPAL REGISTER
  • 06 Mar 2023 — ATTORNEY REVIEW COMPLETED
  • 06 Mar 2023 — LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
  • 06 Mar 2023 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
  • 01 Mar 2023 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
  • 18 Jan 2023 — EXTENSION OF TIME TO OPPOSE RECEIVED
  • 20 Dec 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 20 Dec 2022 — PUBLISHED FOR OPPOSITION
  • 15 Dec 2022 — LETTER OF PROTEST EVIDENCE FORWARDED

View this trademark record on Marksy